The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status.

摘要

The prognostic significance of multilineage dysplasia (MLD) in acute myeloid leukemia patients with intermediate-risk cytogenet-ics (IR-AML) presenting as de novo disease is unclear. Falini et al have recently analyzed the biologic and prognostic significance of MLD in IR-AML and did not find any impact of MLD on survival in patients harboring NPM1 mutations. Moreover, in a subgroup of IR-AML patients with wild-type NPM1 from one of the participating institutions (Munich Leukemia Laboratory), no difference in outcome according to the presence of dysplastic features was observed. To clarify the prognostic significance of MLD in this cytogenetic category, we analyzed a cohort of 130 patients (51% female; median age, 53 years, range, 18-74 years) diagnosed consecutively with de novo IR-AML in our institution from 1994 to March 2010 and treated with intensive chemotherapy.